The healthcare industry has welcomed the government’s notification amending the Uniform Code for Marketing Practices in Medical Devices (UCMPMD). Issued through Circular 3/2025 by the Ministry of Chemicals and Fertilizers, the revised framework introduces mandatory annual disclosures, simplified reporting formats, and clearer valuation rules for free samples.
Key Compliance Requirements
Under the amended code, chief executives or managing directors of medical device companies must now file annual declarations of marketing expenditure within two months of the financial year’s close. For FY25, the deadline has been extended to 30 September 2025.
The revised code also caps free evaluation samples at 2 percent of domestic sales. Companies must record valuation at stockist price if samples are manufactured in-house, or at purchase price if sourced externally. Additionally, firms must disclose expenses on samples, CME programmes, event sponsorships, and specialist doctor international travel, lodging, and hospitality using a newly prescribed annexure format.
Stricter Ethical Provisions
As reported by Express Healthcare, the framework further strengthens ethical marketing practices by prohibiting gifts, cash grants, and personal travel or hospitality benefits for healthcare professionals and their families. Industry associations must now retain disclosure data for five years and ensure compliance, while violations will attract stricter penalties.
Industry Reactions
AiMeD’s Perspective
Rajiv Nath, Forum Coordinator, AiMeD, welcomed the notification:
“At AiMeD, we appreciate the Universal Code of Ethical Marketing of Medical Devices and the simplified annual reporting format. The Code promotes ethical and transparent marketing, fostering fair competition and strengthening the reputation of both domestic and global manufacturers. Patients benefit through safer devices, reliable information, and protection from exploitative promotions.”
MTaI’s View
Pavan Choudary, Chairman, MTaI, noted the dual implications of the amendments:
“We acknowledge the UCMPMD amendments and are reviewing the details. While the revised framework provides greater clarity for the MedTech industry, it also places significant responsibility on industry associations to ensure compliance and safeguard member data. MTaI has already formed an Ethics Committee and updated our web portal in line with UCMPMD requirements, and we are preparing to take on the additional responsibilities.”
A Step Toward Greater Transparency
By mandating detailed disclosures, capping free samples, and prohibiting personal benefits, the amended UCMPMD framework seeks to strengthen ethical marketing practices in the MedTech sector. These measures aim to ensure transparency, accountability, and patient-first practices, while placing a shared responsibility on both companies and industry associations.